

Available online at www.sciencedirect.com

science
$$d$$
 direct

Journal of Pharmaceutical and Biomedical Analysis 35 (2004) 769–777



www.elsevier.com/locate/jpba

CE versus HPLC for the dissolution test in a pharmaceutical formulation containing acetaminophen, phenylephrine and chlorpheniramine

A. Marín, C. Barbas*

Facultad de CC Experimentales y de la Salud, Universidad San Pablo-CEU, Urbanización Montepríncipe, Boadilla del Monte, 28668 Madrid, Spain

Received 30 December 2003; received in revised form 5 March 2004; accepted 7 March 2004

Available online 18 May 2004

Abstract

A new polar reverse phase stationary phase has permitted our group to develop and validate an isocratic HPLC method for the simultaneous determination of acetaminophen, phenylephrine and chlorpheniramine in capsules as pharmaceutical formulation after their dissolution test. Final optimised chromatographic conditions employed a Supelco Discovery[®] HS PEG column (polyethylene glycol), 5 μ m, 15 cm × 0.46 cm. The mobile phase was 20 mM phosphate buffer at pH 7.0/acetonitrile 80:20 (v/v) at a flow rate of 1 ml/min. UV detection was performed at 210 nm for phenylephrine and chlorpheniramine and at 305 nm for acetaminophen. On the other hand, to evaluate the capability of CE to work in a routine analytical method fulfilling the pharmaceutical requirements and to study the behaviour of the technique with these compounds, we developed a CE method with the same objective. Normal and reverted polarity, the pH and concentration of the buffer, and the presence and concentration of surfactants were assayed. Forty millimolar phosphate buffer at pH 6.20 with 0.5 mM SDS at 30 kV in an uncoated silica capillary provided a runtime of 4.5 min to separate the three analytes and the excipients. Moreover, parameters affecting precision in CE, such as the injection of buffer after the sample to refill the capillary were also tested. After development, the validation was performed in parallel for HPLC and CE with the same standards and samples to avoid differences due to the manipulation. The validation parameters of both techniques were adequate for the intended purpose.

© 2004 Elsevier B.V. All rights reserved.

Keywords: Common cold; Capsules; Polyethylene glycol; Validation

1. Introduction

* Corresponding author. Tel.: +34-91-372-4711; fax: +34-91-351-0475.

E-mail address: cbarbas@ceu.es (C. Barbas).

Pharmaceutical formulations against the common cold use to contain compounds in very different proportion and with very different polarities such as acetaminophen, phenylephrine and chlorpheniramine. Due to these characteristics and because of diverse

^{0731-7085/\$ –} see front matter @ 2004 Elsevier B.V. All rights reserved. doi:10.1016/j.jpba.2004.03.003

properties inherent to their formulation and desired action, these preparations offer an analytical problem. Even more, when analysing the dissolution test samples where the concentrations of some of the actives can be very low.

Dissolution test is considered to be one of the most important quality control tests performed on pharmaceutical dosage forms because it is a qualitative tool which can provide valuable information about biological availability of a drug as well as batch-to-batch reproducibility [1–4]. The analysis of dissolution test samples is usually carried out using UV spectrophotometry or HPLC for complex combinations of products. In a previous work [5] we carried out a detailed review of the analytical methods published for measuring some of these substances, alone or in different combinations. Three methods in the literature report the simultaneous quantification of acetaminophen, chlorpheniramine and phenylephrine, but none of them applied for dissolution test. The method of Senyuva and Ozden [6] permits the rapid determination of the three actives in combined pharmaceutical dosage forms using a Bondapak CN column, nevertheless acetaminophen is not separated from the solvent front, with the corresponding quantification problems, and there is no space for the impurities. The method of Kanumula et al. [7] that uses wavelength programming and pseudoephedrine hydrochloride as internal standard and the method developed by Krieger [8] for the separation of acetaminophen in analgesic preparations containing chlorpheniramine maleate, phenylephrine hydrochloride, and other active components by HPLC. Other reports describe the simultaneous separation by HPLC of acetaminophen, chlorpheniramine and phenylpropanolamine, which is a compound that appears in some formulations instead of phenylephrine [9-11]. In our last work we developed and validated an isocratic HPLC method for the simultaneous determination of the three actives in capsules as pharmaceutical formulations, including the separation of impurities and excipients [12]. The chromatographic method was an interesting advance because it was isocratic and the run time was less than 12 min. It was developed by using new polar reverse phase stationary phases in HPLC, such as polyethyleneglycol, that provide with specific selectivity.

On the other hand, in spite of the quality control analysis of pharmaceuticals is currently performed predominantly using HPLC, many pharmaceutical analysis laboratories have an increasing presence of CE instrumentation, so CE offers a real and attractive alternative to HPLC. CE in many instances can have different advantages over HPLC in terms of rapid method development, reduced operating costs and increased simplicity [13]. In many laboratories reliable and reproducible results are routinely obtained in CE if the methods are correctly optimised, described, validated and applied by operators using good working practices. At the moment, only mixtures of acetaminophen and chlorpheniramine alone or in combination with other cold medicines such as phenylpropanolamine has been separated by MECC [14-18] and by EKC employing bile salts [19]. The aim of the present work was the optimisation and validation of chromatographic and electrophoretic methods for the measurement of acetaminophen, phenylephrine and chlorpheniramine in capsules as pharmaceutical formulation after their dissolution test.

2. Experimental

2.1. Chemicals

Standards of acetaminophen, phenylephrine and chlorpheniramine as well as capsules and excipients of the speciality were kindly provided by CINFA, S.A. (Pamplona, Spain). Phosphoric acid 85% and SDS were from Merck (Darmstadt, Germany). CTAB was from Fluka (Madrid, Spain). NaOH and the other organic solvents were HPLC grade from Scharlab (Barcelona, Spain).

2.2. Chromatographic system

HPLC system was an Agilent technologies 1100 series (Las Rozas, Madrid, España) provided with an automatic injector, a diode-array detector and a column oven. The chromatographic analysis were performed on a 5 μ m particle, Discovery HS PEG (polyethylene glycol) column (Supelco, Alcobendas, Madrid, Spain), 15 cm × 0.46 cm, kept at 35 °C.

Final chromatographic conditions were an isocratic elution with phosphate buffer 20 mM at pH = 7.0/acetonitrile, 80:20 (v/v). The phosphate buffer was prepared from H₃PO₄ by adding NaOH to reach the pH 7.0. The flow rate was 1 ml/min and the injection volume was 50 μ l. UV detection was performed at 210 nm for phenylephrine and chlorpheniramine, because at this wavelength the sensitivity was higher than in other more characteristic wavelengths and it was necessary for the detection of these minor compounds. For acetaminophen 305 nm was employed. At this wavelength the absorbance for this compound is very low and the signal is not saturated with the large amount of acetaminophen present in the sample to be

able to detect the minor compounds simultaneously.

2.3. Capillary electrophoresis system

Capillary electrophoresis was a P/ACE 5500 (Beckman) with UV detection at 200 nm. The separation was carried out with an uncoated fused-silica capillary (57 cm \times 50 µm i.d.). During the development of the analytical method both polarity modes were tested. Final conditions were normal polarity, injection at the positive end (anode) and detection at the negative end (cathode) with 30 kV of applied potential. Separation buffer was prepared with 40 mM H₃PO₄ made up pH 6.20 with NaOH, and with 0.5 mM SDS added. The injection was by pressure (3.3 bar) first 5 s for sample and then 5 s for buffer. Temperature was maintained at 25 °C. The capillary was flushed between runs with the BGE for 1 min. Fresh new vial buffers were replaced after each six samples.

2.4. Dissolution test system

The dissolution rates of acetaminophen, phenylephrine and chlorpheniramine from commercial capsules were measured using an Erweka dissolution apparatus with six glasses (Gomensoro, Madrid, Spain).

2.5. Preparation of standard solutions

A stock solution of phenylephrine was prepared with 434.0 mg of phenylephrine hydrochloride exactly weighed and dissolved with methanol/water 1:1 (v/v) in a 25 ml volumetric flask. For chlorpheniramine maleate stock solution, 173.6 mg were made up 25 ml with methanol/water 1:1 (v/v). For the reference stock standard, 434.0 mg of acetaminophen were weighed in a 25 ml volumetric flask and 0.5 ml of phenylephrine and chlorpheniramine solutions were added and the volume was made up with methanol/water 1:1 (v/v).

The working standard (corresponding to 100% of each compound dissolved) was prepared with 0.8 ml of the stock standard diluted to 25 ml with purified water.

2.6. Dissolution and analysis procedure

One capsule (~610 mg) was added in each one of the six glasses, using 900 ml of water at 37 ± 0.5 °C as dissolution medium. The equipment was operated with baskets at 100 rpm. Samples aliquots of 10 ml were taken at 45 min and filtered through 0.45 μ m nylon filters to the HPLC or CE vials.

2.7. Optimization of HPLC method

For method development in HPLC, the most important parameters that modify the selectivity in the chromatographic separation such as the pH of the mobile phase, the concentration of the buffer and the organic percentage were studied in order to find a new rapid and precise method to quantify the three actives in capsules after the dissolution test. Results are shown below.

2.8. Optimization of CE method

Selectivity in CZE can be controlled by background electrolyte concentration, pH, organic modifiers, presence of surfactants and polarity. All these parameters were varied and results are summarised below. Moreover, parameters affecting precision in CE, such as the injection of buffer after the sample to refill the capillary were also tested.

2.9. Validation

The validation was performed in parallel for HPLC and CE with the same standards and samples to avoid differences due to the manipulation.

Linearity for standards was tested assaying by triplicate seven levels of concentrations ranging from 6.25 to 125% and corresponding to 34.722 to 694.44 mg/l for acetaminophen; 0.694 to 13.89 mg/l for phenylephrine and 0.278 to 5.56 mg/l for chlorpheniramine. These solutions were prepared with 0.050 to 1.000 ml of the stock standard in 25 ml volumetric flask with purified water. Linearity for samples was tested in the same way, but including the proportional amount of excipients of the capsules.

The accuracy of the method was tested by the percent recoveries and R.S.D. and it was estimated comparing the values obtained in samples linearity, with those in standards linearity.

Instrumental precision was tested by consecutively running six injections each day of the same standard mixture, corresponding to the 100% of the calibration curve.

Method precision was evaluated by processing separately six samples each day of a homogeneous mixture of powder from the capsules plus a clean empty capsule. Samples were independently prepared according to the dissolution procedure with the corresponding standards for calibration.

Method and instrumental intermediate precision data were obtained by repeating intra-assay experiment on a different day.

3. Results and discussion

3.1. HPLC method optimization

Starting conditions were those of our previous work [12], briefly a Supelco Discovery[®] HS PEG column (polyethyleneglycol), that achieved an increased retention of polar species, which are retained away from the solvent front, and decreased retention of non-polar compounds, which reduces the total analysis time. However, as this method was developed for impurity

profiling, it was optimised to obtain a shorter run time in the dissolution assay and to solve the problem due to the polarity of the sample solvent. Small variations on the percentage of acetonitrile in the mobile phase showed little influence in the retention times of more polar compounds, while increasing retention time for chlorpheniramine. 80:20 phosphate buffer/acetonitrile (v/v) was chosen as the best option for the dissolution test. Buffer concentration showed little influence, but 20 mM phosphate buffer seemed to give the best results.

The dissolution medium of the standards resulted critical as much for their chromatographic profile as for the quantification, mainly for phenylephrine, the more polar of them. As it is known less polar solvents facilitate standards dissolution but provide wide and non-Gaussian peaks when injected in a more polar mobile phase. Therefore, standards were initially solved in methanol at a high concentration and a second dilution in water with only 2% methanol in the flask gave to obtain the same profile than the samples dissolved in pure water for the test. Final conditions were summarised in the paragraph of chromatographic conditions and the corresponding chromatograms are shown in Fig. 1. These conditions allowed the maximum degree of optimization in HPLC with the shorter run time, because higher proportion of organic modifier produced overlapping of phenylephrine peak with the shift in the baseline due to the dissolution media.




Fig. 1. Chromatogram of a standard, a synthetic sample, the standard dissolution medium and excipients. Column: Discovery HS PEG (polyethyleneglycol) 5 μ m, 4.6 mm × 150 mm (Supelco). Mobile phase: 80% 20 mM phosphate buffer/20% acetonitrile. Flow: 1 ml/min. λ : 210 nm. Temperature: 35 °C.




Fig. 2. Comparison of the migration times of standards in reverted and normal polarity. Uncoated silica capillary (57 cm \times 75 μ m). 40 mM Phosphate buffer at different pH values with 0.05 mM SDS added for normal polarity or 0.5 mM CTAB for reverted polarity. Applied current 100 μ A (30 kV). Detection at 200 nm.

3.2. CE method development

Next step was method development in CE. Fortunately, once prepared the different buffers, assays are conducted by the equipment unattended. At first instance, polarity was selected by running the three standards at different pHs, and adding 0.05 mM SDS for normal polarity and 0.5 mM CTAB for reverted polarity, applying a constant current of 100 μ A (~30 kV). Results have been summarised in Fig. 2 and as can be seen, at pH 7 with normal polarity, injection at the positive end (the anode) and detection at the negative




Fig. 3. Electropherogram of a mixture of phenylpropanolamine (0.078 mg/ml) phenylephrine (0.043 mg/ml), chlorpheniramine (0.037 mg/ml) and acetaminophen (1 mg/ml). CE conditions: uncoated silica capillary (57 cm \times 75 μ m i.d.). Normal polarity. Background electrolyte: 40 mM phosphate buffer at pH 6.20 with 0.05 mM of SDS. Applied current: 100 μ A. UV detection: 200 nm. Temperature: 25 °C.




Fig. 4. Effect of capillary treatment between runs in the repeatability of the method. Ten electropherograms of a standard mix overlaid and their R.D.S.s (%) for migration times and areas in a capillary conditioning with A: NaOH, H₂O, running buffer and 5 s of injecting sample. B: running buffer and 5 s of injecting sample. C: running buffer and 5 s of injecting buffer after 5 s of sample. CE conditions: uncoated silica capillary (57 cm \times 75 µm i.d.). Normal polarity. Background electrolyte: 40 mM phosphate buffer at pH 6.20 with 0.5 mM of SDS. Applied current: 100 µA. UV detection: 200 nm. Temperature: 25 °C.

end (the cathode), the three actives appeared with the shorter retention time and those were the conditions selected for a further optimisation. When buffers with pH ranging from 6.00 to 8.00 with 0.2 increments were

tested, pH 6.2 gave the best resolution with minimum analysis time, including the separation of phenylpropanolamine, which can be included in some formulations instead of phenylephrine as shown Fig. 3. The




Fig. 5. Electropherogram of a standard, a synthetic sample, the standard dissolution medium and excipients. CE conditions: uncoated silica capillary (57 cm \times 75 μ m i.d.). Normal polarity. Background electrolyte: 40 mM phosphate buffer at pH 6.20 with 0.5 mM of SDS. Applied voltage: 30 kV. Injection time: 5 s sample + 5 s of running buffer. UV detection: 200 nm. Temperature: 25 °C.

effect of buffer concentration in the background electrolyte was also tested and, as expected, lower concentrations provided lower migration times. Therefore, 40 mM phosphate was chosen because it gave baseline resolution and shorter running time. The concentration of surfactant was also tested at concentrations under the critical micellar concentration. 0.5 mM SDS slightly improved acetaminophen peak shape providing higher efficiency and not affecting the other two compounds and it was included in the buffer. Finally, it was observed that the presence of a small percentage of organic modifier in the BGE, methanol or acetonitrile, deteriorated the aspect of the peaks and they were avoided.

One of the weak points in many CE methods is the description of capillary treatment between runs and it greatly affects reproducibility. In the Fig. 4A it can be

observed the overlay of ten injections corresponding to a capillary conditioned with sodium hydroxide, water and running buffer. In Fig. 4B the capillary was conditioned only with the running buffer. Meanwhile, in Fig. 4C the effect of injecting a buffer plug after the sample, in a capillary conditioned with running buffer, can be appreciated. This treating was previously recommended by Altria and Fabre [20]. In all cases the calculated R.S.D. for migration times and areas are shown. As can be observed, they were lower in the last case. Therefore, BGE injection after the sample is highly recommended to obtain more precise methods.

Finally, 40 mM phosphate buffer at pH 6.20 with 0.5 mM SDS at 30 kV in an uncoated silica capillary provided a runtime of 3.5 min to separate the three analytes and the excipients as it is shown in Fig. 5.

Table 1

Main validation parameters of the HPLC and CE methods for linearity

Linearity and range	HPLC	CE	
Acetaminophen Linearity range (%) (mg ml ⁻¹)	25–125 0.13889–0.69444	12.5–125 0.06944–0.69444	
Standards linearity ($a \pm CL$) ($b \pm CL$) (r)	89 ± 37 4455 ± 81 0.9995	$\begin{array}{c} 11369 \pm 4078 \\ 1819735 \pm 9654 \\ 0.99995 \end{array}$	
Sample linearity $(a \pm CL)$ $(b \pm CL)$ (r)	93 ± 27 4429 ± 58 0.9998	$\begin{array}{r} 12256 \pm 7647 \\ 1809130 \pm 18103 \\ 0.9998 \end{array}$	
Phenylephrine Linearity range (%) (mg ml ⁻¹)	25–125 0.00278–0.01389	6.25–125 0.00069–0.01389	
Standards linearity ($a \pm CL$) ($b \pm CL$) (r)	$\begin{array}{c} 111 \pm 37 \\ 114783 \pm 4043 \\ 0.998 \end{array}$	$\begin{array}{c} 88 \pm 124 \\ 1161261 \pm 15925 \\ 0.9996 \end{array}$	
Sample linearity $(a \pm CL)$ $(b \pm CL)$ (r)	$\begin{array}{r} 119 \pm 23 \\ 112288 \pm 2477 \\ 0.9993 \end{array}$	$\begin{array}{c} 65 \pm 153 \\ 1140127 \pm 19678 \\ 0.9993 \end{array}$	
Chlorpheniramine Linearity range (%) (mg ml ⁻¹)	25–125 0.00111–0.00556	25–125 0.00111–0.00556	
Standards linearity ($a \pm CL$) ($b \pm CL$) (r)	-16 ± 6 113677 \pm 1648 0.9997	-67 ± 135 667228 ± 36489 0.996	
Sample linearity $(a \pm CL)$ ($b \pm CL$) (r)	-15 ± 22 108246 \pm 5850 0.996	-39 ± 103 600183 ± 27732 0.997	

 Table 2

 Accuracy and recovery of the HPLC and CE methods

Accuracy	HPLC	CE	
Acetaminophen			
Standards	100 ± 1	99.8 ± 0.9	
R.S.D. (%)	1.738	1.754	
Samples	100 ± 1	100 ± 1	
R.S.D. (%)	1.546	2.256	
Phenylephrine			
Standards	99 ± 2	100 ± 1	
R.S.D. (%)	3.788	3.071	
Samples	100 ± 1	101 ± 2	
R.S.D. (%)	2.627	3.364	
Chlorpheniramine			
Standards	100 ± 1	101 ± 3	
R.S.D. (%)	2.126	5.786	
Samples	101 ± 2	100 ± 2	
R.S.D. (%)	3.945	3.778	

3.3. Validation

After development, the validation was performed in parallel for HPLC and CE with the same standards and samples to avoid differences due to the manipulation. It is important to point out that validation was performed to check the performance of the analytical methods and not the dissolution test. Selectivity was confirmed by separated injection of excipients and solvents from standards.

Table 3

Instrumental precision of the HPLC and CE methods

Main validation parameters of the method for linearity are shown in Table 1.

As can be observed limits of quantification, the lower value in the range, were lower for CE than for HPLC in spite of being CE a technique considered less sensible due to the injection of very small volumes. It was related to the higher precision in the areas of the corresponding peaks in CE at lower levels of concentration than in HPLC and it could be due to the higher peak efficiency in CE that provides better signal/noise values. Nevertheless, both techniques provide a linear range wide enough for the three actives and no bias was observed.

Accuracy was evaluated with recoveries obtained in the analysis of synthetic samples prepared in the laboratory through the linear range at seven levels of concentrations, from 6.25 to 125% and compared with the corresponding standards. The mean recoveries included the 100% for both techniques as it is shown in Table 2. The range was spanned up to 6.25% of the theoretical concentrations to allow us the use of the method for dissolution profiling tests. The dissolution test requirement of pharmacopoeia with reference to the acceptance criteria are 80% for the three actives, which is included into the validated range.

R.S.D.s in instrumental precision were lower for HPLC, but they were good in both cases, as much for one as for two different days (Table 3). In spite of

Instrumental precision		HPLC	CE	
Acetaminophen				
Intra-assay $(n = 6)$	Mean (mg/ml) \pm C.L R.S.D. (%)	$\begin{array}{c} 0.5568 \pm 0.0001 \\ 0.022 \end{array}$	$\begin{array}{c} 0.557 \pm 0.002 \\ 0.303 \end{array}$	
Intermediate $(n = 12)$	Mean (mg/ml) \pm C.L R.S.D. (%)	$\begin{array}{c} 0.5574 \pm 0.0006 \\ 0.181 \end{array}$	$\begin{array}{c} 0.557 \pm 0.001 \\ 0.321 \end{array}$	
Phenylephrine				
Intra-assay $(n = 6)$	Mean (mg/ml) \pm C.L R.S.D. (%)	$\begin{array}{c} 0.01110 \pm 0.00004 \\ 0.341 \end{array}$	$\begin{array}{c} 0.01110 \pm 0.00006 \\ 0.548 \end{array}$	
Intermediate $(n = 12)$	Mean (mg/ml) ± C.L R.S.D. (%)	$\begin{array}{c} 0.01110 \pm 0.00002 \\ 0.343 \end{array}$	$\begin{array}{c} 0.01110 \pm 0.00004 \\ 0.605 \end{array}$	
Chlorpheniramine				
Intra-assay $(n = 6)$	Mean (mg/ml) \pm C.L R.S.D. (%)	$\begin{array}{c} 0.00446 \pm 0.00003 \\ 0.705 \end{array}$	$\begin{array}{c} 0.00446 \pm 0.00005 \\ 1.114 \end{array}$	
Intermediate $(n = 12)$	Mean (mg/ml) \pm C.L R.S.D. (%)	$\begin{array}{c} 0.00446 \pm 0.00002 \\ 0.714 \end{array}$	$\begin{array}{c} 0.00446 \pm 0.00003 \\ 1.083 \end{array}$	

Table 4						
Method p	recision	of the	HPLC	and C	CE n	ethods

Method precision		HPLC	CE
Acetaminophen			
Intra-assay $(n = 6)$	Mean (mg/cap) \pm C.L	506 ± 4	501 ± 5
	R.S.D. (%)	0.792	0.935
Intermediate $(n = 12)$	Mean (mg/cap) \pm C.L	504 ± 4	500 ± 3
	R.S.D. (%)	1.237	0.930
Phenylephrine			
Intra-assay $(n = 6)$	Mean (mg/cap) \pm C.L	10.2 ± 0.4	9.8 ± 0.4
-	R.S.D. (%)	3.487	4.315
Intermediate $(n = 12)$	Mean (mg/cap) \pm C.L	10.2 ± 0.2	10.1 ± 0.3
	R.S.D. (%)	3.686	5.192
Chlorpheniramine			
Intra-assay $(n = 6)$	Mean (mg/cap) \pm C.L	4.0 ± 0.1	3.5 ± 0.1
	R.S.D. (%)	2.965	3.495
Intermediate $(n = 12)$	Mean (mg/cap) \pm C.L	4.0 ± 0.1	3.5 ± 0.1
	R.S.D. (%)	4.126	5.497

the improvement obtained with the injection of BGE after the sample, method precision was the weakest point for CE when comparing both techniques, but still precision can be considered acceptable for the purpose (Table 4).

4. Conclusions

Although in the present work the chromatographic method was only optimised from a previous one, which was developed for the main components and impurities assay, in general terms, method development is easier in CE than in HPLC, because different buffers can be tested automatically. Validation parameters for this particular situation were adequate for both methods, although linearity has resulted slightly better and precision slightly poorer for CE. Analysis time is shorter with the CE method and solvent consumption was considerably lower, which is a great economical benefit. Nevertheless, buffer preparation was a bit more difficult due to the presence of the surfactant. Finally, the main drawback to establish the CE method as routine in the pharmaceutical laboratory was that trained staff is more common to work with HPLC than with CE.

References

 U.V. Banakar, M.C. Makoid, Drug Dissolution and Bioavailability (seminar handouts), Technomic Publishing AG, Basel, Switzerland, 1994.

- [2] B. Hoener, L.Z. Benet, in: G.S. Banker, C.T. Rhodes (Eds.), Modern Pharmaceutics, Marcel Dekker, New York, 1990.
- [3] The United States Pharmacopeia 27, NF 22, Revision, United States Pharmacopeial Convention Inc., Rockville, USA, 2004.
- [4] European Pharmacopoeia, vol. 4.8, fourth ed., 2004.
- [5] A. Marín, E. García, A. García, C. Barbas, J. Pharm. Biomed. Anal. 29 (2002) 701–714.
- [6] H. Senyuva, T. Ozden, J. Chromatogr. Sci. 40 (2002) 97– 100.
- [7] G.V. Kanumula, B. Raman, I.C. Bhoir, Indian Drugs 38 (2001) 203–207.
- [8] D.J. Krieger, J. Assoc. Off. Anal. Chem. 67 (1984) 339– 341.
- [9] V. Das Gupta, A.R. Heble, J. Pharm. Sci. 73 (1984) 1553– 1556.
- [10] X. Zhao, B. Tan, H. Zhang, Huaxi Yaoxue Zazhi 13 (1998) 271–273.
- [11] G. Indrayanto, A. Sunarto, Y. Adriani, J. Pharm. Biomed. Anal. 13 (1995) 1555–1559.
- [12] A. García, F.J. Rupérez, A. Marín, A. de la Maza, C. Barbas, J. Chromatogr. B 785 (2003) 237–243.
- [13] K.D. Altria, A.B. Chen, L. Cloths, LC GC Europe (CE Currents) 2–7 December 2001.
- [14] Y.J. Heo, K.-J. Lee, Yakhak Hoechi 41 (1997) 539-546.
- [15] S. Ji, Y. Chai, Y. Wu, D. Liang, Z. Xu, X. Li, Yaowu Fenxi Zazhi 18 (1998) 170–173.
- [16] D. Zou, X. Wu, G. Nan, Yaowu Fenxi Zazhi 17 (1997) 160– 163.
- [17] B.Y. Sun, A.J. Huang, Y.L. Sun, Z.P. Sun, Chin. Chem. Lett. 8 (1997) 619–622.
- [18] L. Suntornsuk, Electrophoresis 22 (2001) 139-143.
- [19] H. Nishi, T. Fukuyama, M. Matsuo, S. Terabe, J. Chromatogr. 498 (1990) 313–323.
- [20] K.D. Altria, H. Fabre, Chromatographia 40 (1995) 313-320.